Hyderabad, Andhra Pradesh, India — Ocimum Biosolutions, a leading provider of genomic solutions, today announced the launch of its quantitative real-time polymerase chain reaction (qRT-PCR) services in India. This technology is already in use at Gene Logic, an Ocimum Biosolutions company. qRT-PCR technology is routinely used for a variety of applications such as expression analysis of candidate genes, validation of microarrays, gene copy number determination and target detection with TaqMan® probes or SYBR green.

The qRT-PCR services offered by Ocimum include sample preparation such as RNA/DNA extraction, purification and QC; design of high-performance RT-PCR assays and customized PCR primers/ probe based on TaqMan® assay or SYBR green; technical support for experimental design based on client’s need and criteria; and data analysis services including delta-delta Cts values and graphical presentation of genes with unique expression and differential regulation patterns.

Ms. Anu Acharya, CEO, Ocimum Biosolutions, said, “qRT-PCR technology finds applications in several areas such as drug target and biomarker discovery, food authenticity, mutation detection, clinical microbiology, validation of array data and gene quantification. Our services will offer clients high technical sensitivity, high precision, high throughput, lower turn-around-times and decreased costs.”

About Ocimum Biosolutions

Ocimum Biosolutions is a leading integrated global genomics outsourcing partner with solutions spanning Bioresearch Design and Execution; Data Analytics and Insights; Laboratory, Sample & Data Management; and Integrated Solutions. Ocimum provides comprehensive genomic services and reference databases; data analysis; biorepository services such as sample accrual & collection, IRB approvals, CRO training, sample, clinical data capture and management; life science lab information management solutions; and also offers both research level and GLP-compliant services. Ocimum has presence in three continents, the United States, Europe and India and will have globally certified GLP and CLIA labs to enable drug discovery, development and diagnostics. Over 2/3rd of the top 25 pharma companies, leading research institutes and emerging biotech companies worldwide have chosen us as their preferred outsourcing partner and utilize our expertise for understanding underlying mechanisms of diseases, discovery and prioritization of gene targets and biomarkers.

Our global infrastructure, standardized procedures, capacity, expertise and highly skilled staff support drug development programs from pre-clinical target development and toxicogenomic assessment to clinical biomarker identification and patient stratification. In creating the world’s largest commercial gene expression databases – BioExpress® and ToxExpress®, we have developed expertise and capabilities that are unparalleled in the genomic services industry. Ocimum has been consistently ranked as India’s fastest growing biotechnology company and one of the fastest growing technology companies over the last five years by Deloitte Touche Tohmatsu.

For more information, please visit www.ocimumbio.com.